Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

NCT02194075 Phase 4 COMPLETED

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

Details

Lead sponsor	Guangdong Provincial People's Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2013-10
Completion	2015-10

Conditions

• Obsessive Compulsive Disorder

Interventions

• Fluvoxamine+Methylphenidate hydrochloride
• Fluvoxamine+sugar pill

Primary outcomes

• Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — 8 weeks

Countries

China